TITLE

THE EFFECT OF CONTINUED ADMINISTRATION OF SUBLINGUAL HEPARIN ON THE FAT TOLERANCE TEST

AUTHOR(S)
Shaftel, Herbert E.; Padernacht, Elias
PUB. DATE
April 1961
SOURCE
Angiology;Apr1961, Vol. 12 Issue 4, p124
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the effect of the continued administration of sublingual heparin in treating athersclerosis on the fat tolerance test. Capabilities of heparin in treating atherosclerosis; Pros and cons in the therapeutic use of heparin; Clinical ability of heparin that triggers the difficulty in finding the accurate result of the fat tolerance test.
ACCESSION #
16432667

 

Related Articles

  • THE EFFECT OF SUBLINGUAL HEPARIN ON LIPOPROTEIN DISTRIBUTION IN ATHEROSCLEROSIS. Biancani, G. // Angiology;Apr1961, Vol. 12 Issue 4, p119 

    Focuses on the capability of sublingual heparin in restoring the distribution of lipoprotein in the body in the treatment of atherosclerosis. Cause of atherosclerosis; Importance of the clearing factor of the heparin in its capacity in treating atherosclerosis; Developments in the heparin therapy.

  • Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations. Leong, Wendy; Hoppensteadt, Debra A. // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p293 

    This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.

  • The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Jacques Chanard; Sylvie Lavaud; Hervé Maheut; Isabelle Kazes; Fabien Vitry; Philippe Rieu // Nephrology Dialysis Transplantation;Jun2008, Vol. 23 Issue 6, p2003 

    Background. The AN69 ST haemodialysis membrane, a new membrane resulting from coating polyethyleneimine upon the polyacrylonitrile surface, binds heparin. In patients at risk of bleeding, a pilot study has demonstrated the efficient anticoagulant effect of this heparin-coated membrane. Study...

  • THE EFFECT OF HEPARIN ON CHOLESTEROL PARTITION, LIPOPROTEINS AND ATHEROSCLEROSIS IN EXPERIMENTAL HYPERCHOLESTEROLEMIA. Moses, Campbell; Rhodes, Grace L. // Angiology;Oct1954, Vol. 5 Issue 5, p429 

    Investigates the effect of heparin on cholesterol partition, lipoproteins and atherosclerosis in experimental hypercholesterolemia. Absence of significant reduction in aortic atherosclerosis in the blood fractions; Failure of heparin to retard the development of atherosclerosis; Impact of high...

  • Secondary Prophylaxis with Warfarin for Venous Thromboembolism. Büller, Harry R.; Prins, Martin H. // New England Journal of Medicine;8/14/2003, Vol. 349 Issue 7, p702 

    Editorial. Offers an editorial on the two phases in the treatment of patients with symptomatic venous thromboembolism. Therapy that consists of either subcutanous low-molecular-weight heparin or intravenous unfractionated heparin; Phase involving oral vitamin K antagonists such as warfarin;...

  • Prophylaxis for Thromboembolism in Hospitalized Medical Patients. Francis, Charles W. // New England Journal of Medicine;4/5/2007, Vol. 356 Issue 14, p1438 

    The article discusses whether an older man who presented to the hospital with fever, cough, and dyspnea should receive thromboprophylaxis. The patient exhibited risk factors for venous thromboembolism. Various treatments for venous thrombosis are described, including nonpharmacologic therapies...

  • Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital. Xu, Huimin; Cai, Hongwen; Qian, Zhongshu; Xu, Geng; Yan, Xiaofeng; Dai, Haibin // BMC Cardiovascular Disorders;2012, Vol. 12 Issue 1, p118 

    Background: Low-molecular-weight heparins (LMWHs) are safe and effective anticoagulant options for cardiovascular patients when applied as body weight-adjusted doses. However, there are some barriers that make it difficult to implement weight-adjusted doses in clinical practice. Therefore, it is...

  • Treatment of venous thromboembolism: duration and new options. Huisman, Menno V. // Hematology Journal;2004 Supplement 3, Vol. 5, pS24 

    Studies the treatment of venous thromboembolism. Initial treatment of choice; Evidence for the need of heparin; Optimal duration of anticoagulant therapy; Management of patients with an increased risk of recurrence.

  • Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention. Wong, Graham C.; Giugliano, Robert P.; Antman, Elliott M. // JAMA: Journal of the American Medical Association;1/15/2003, Vol. 289 Issue 3, p331 

    Context: Low-molecular-weight heparins (LMWHs) possess several potential pharmacological advantages over unfractionated heparin as an antithrombotic agent. Objective: To systematically summarize the clinical data on the efficacy and safety of LMWHs compared with unfractionated heparin across the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics